Salt Lake City, UTNCT06395285Now EnrollingIRB Ready

ROSAH Clinical Trial in Salt Lake City, UT

Access cutting-edge rosah treatment through this phase 1 clinical trial at a research site in Salt Lake City. Study-provided care at no cost to qualified participants.

Sponsored by Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)

Quick Self-Assessment

See if you qualify for this Salt Lake City location

Preparing your pre-screening questions…

Expert Care in Salt Lake City

Access rosah specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related rosah treatment provided free

Apply for This Salt Lake City Location

Check if you qualify for this rosah clinical trial in Salt Lake City, UT

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Salt Lake City

    Convenient for UT residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Salt Lake City site if eligible
  4. 4Begin participation

About This ROSAH Study in Salt Lake City

The purpose of this study is to evaluate the safety and tolerability of DF-003 in retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and migraine headache (ROSAH) syndrome patients.

Sponsor: Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)

Who Can Participate

Inclusion Criteria

Sufficient understanding of the purpose and procedures required for the study.
Body mass index (BMI) of 18.0 to 35.0 kg/m2, inclusive.
Genetic testing for ALPK1 mutations that has been shown to be associated with ROSAH syndrome (e.g. T237M or Y254C, or T237A mutations).
Signs of uveitis (anterior and/or posterior) in the eye (e.g. macula edema, optic nerve edema, retinal vasculitis, or retinal vascular leakage).
Patients must be deemed healthy except for diagnosis of ROSAH syndrome and its clinical manifestation.
Patients must be at least 18 years of age but no older than 65 years of age at the time of Screening.

Exclusion Criteria

Males who plan to father a child or donate sperm while enrolled in this study or within 90 days after the last dose of study drug.
Females who are pregnant, breastfeeding, planning to become pregnant, or planning to donate eggs while on study medication or within 90 days after the last dose of study drug.
Use of any of the following prohibited medications:
Agents that are known to have systemic anti-inflammatory responses or high risk for nephrotoxicity or hepatotoxicity
Moderate CYP3A4 inhibitors: e.g., amiodarone, amprenavir, conivaptan, delavirdine, diltiazem, erythromycin, fluconazole, fosamprenavir, imatinib, miconazole, verapamil, grapefruit juice, cat's claw (Dolichandra unguis-cati), Echinacea augustifolia, wild cherry, chamomile, licorice
Strong CYP3A4 inhibitors: e.g., ceritinib, clarithromycin, cobicistat, elvitegravir/ritonavir, idelalisib, indinavir/ritonavir, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, paritaprevir/ritonavir, ombitasvir/paritaprevir/ritonavir (and/or dasabuvir), posaconazole, ritonavir, saquinavir/ritonavir, telithromycin, tipranavir/ritonavir, voriconazole.
Strong CYP3A4 inducers: apalutamide, carbamazepine, enzalutamide, ivosidenib, lumacaftor/ivacaftor, mitotane, phenytoin, rifampin, St. John's wort.
Agents known to cause Torsade de Pointes: Disopyramide, procainamide, quinidine, sotalol, azithromycin, clarithromycin, erythromycin, ciprofloxacin, levofloxacin, moxifloxacin, fluconazole, ketoconazole, pentamidine, voriconazole, haloperidol, thioridazine, ziprasidone, citalopram, escitalopram, dolasetron, droperidol, granisetron, and ondansetron
Investigational agents (small molecules and oligonucleotides), vaccines, or invasive medical devices within 28 days (4 weeks, or 5 half-lives, whichever is longer) prior to enrollment or having received a biological product within 6 months prior to enrollment.
History of significant hypersensitivity to products related to DF-003 (including excipients of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs.
Recent (within 3 months prior to screening) or acute changes in the following laboratory values:
Platelet count ≤ 120,000/mm3, or
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> ULN
Bilirubin (total, direct) \> ULN or
International Normalization Ratio (INR) \> ULN, or
Serum albumin less than the lower limit of normal, or
Estimated creatinine clearance \< 70 mL/min/1.73 m2 at Screening, calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula, or
Hemoglobin A1c (HbA1c) \> 8%.
Moderate or severe hepatic impairment (categorized as Child-Pugh class B and C, respectively, on the Child-Pugh Score for Cirrhosis Mortality)

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Salt Lake City?

Yes, this clinical trial (NCT06395285) has an active research site in Salt Lake City, UT that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

ROSAH Treatment Options in Salt Lake City, UT

If you're searching for rosah treatment options in Salt Lake City, UT, this clinical trial (NCT06395285) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Salt Lake City research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced rosah specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all rosah clinical trials near you to find additional studies recruiting in your area.

More Sleep Apnea Trials in Salt Lake City, UT

See all sleep apnea clinical trials recruiting in Salt Lake City — not just this study.

Browse Sleep Apnea Trials in Salt Lake City →

Browse More Trials by Condition

Sleep Apnea TrialsAll Conditions →

Ready to Join in Salt Lake City?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Salt Lake City, UT